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Chronic wasting diseaseD) is an efﬁciently transmitted spongiform encephalopathy of cervids. Whether
CWD could represent a threat to non-cervid species remains speculative. Here we show that brain
homogenates from several CWD-susceptible non-cervid species, such as ferrets and hamsters, support
ampliﬁcation of PrPCWD by sPMCA, whereas brain homogenates from CWD-resistant species, such as
laboratory mice and transgenic mice expressing human PrPC [Tg(HuPrP) mice], do not. We also investigated
whether several North American species that share the environment with cervids would support
ampliﬁcation of PrPCWD by sPMCA. Three native rodent species, including voles and ﬁeld mice, supported
PrPCWD ampliﬁcation, whereas other species (e.g. prairie dog, coyote) did not. Analysis of PrP sequences
suggests that an ability to support ampliﬁcation of PrPCWD in trans-species sPMCA is correlated with the
presence of asparagine at position 170 of the substrate species PrP. Serial PMCA may offer insights into
species barriers to transmission of CWD.
© 2009 Elsevier Inc. All rights reserved.Introduction
Chronic wasting disease (CWD) of deer, elk and moose is a prion
disease ﬁrst identiﬁed in the Rocky Mountain region and now
recognized in 15 states, Canada, and one Asian country (Williams,
2005;Williams and Young,1980). Like other transmissible spongiform
encephalopathies (TSEs) such as ovine scrapie, bovine spongiform
encephalopathy (BSE) and human Creutzfeldt–Jakob Disease (CJD),
CWD is caused by the conversion of normal, protease-sensitive PrPC
protein to a misfolded, protease-resistant conformation (PrPRES)
which accumulates in the central nervous and lymphoid systems
and leads to wasting and spongiform encephalopathy (Sigurdson
et al., 2002, 1999; Spraker et al., 2002).
The facile spread of CWD is different from most TSEs and may
reﬂect the transmission of infectious prions from the saliva and excreta
of infected cervids (Mathiason et al., 2006; Safar et al., 2008).While the
known natural host range for CWD is limited to cervids, some non-
cervid species, e.g. ferrets and hamsters, can be infected experimen-
tally (Bartz et al., 1998; Harrington et al., 2008; Raymond et al., 2007;
Sigurdson et al., 2008a). Trans-species transmission of priondiseases isoover).
ll rights reserved.infrequent due to the species barrier phenomenon, which may be
mediated by differences in PrPC sequence, prion strain, and other still
unknown factors (Bartz et al.,1994; Harrington et al., 2008; Kong et al.,
2005; Piening et al., 2006; Raymond et al., 2000). Because in vivo
susceptibility studies in candidate outbred species are protracted and
costly, a comprehensive analysis of CWD species barriers by direct in
vivo exposure has yet to emerge. Thus, the existence of non-cervid
reservoirs for CWD in the wild remains conceivable.
The advent of proteinmisfolding cyclic ampliﬁcation (PMCA) for in
vitro prion ampliﬁcation (Saborio et al., 2001) offers the potential to
assess the CWD species barrier by evaluating the permissiveness of a
given species brain substrate to support PrPC-to-PrPRES conversion
(Jones et al., 2007; Saa et al., 2006; Soto et al., 2005). When PrPC and
PrPRES from the same species are used, in vitro ampliﬁcation preserves
the biochemical characteristics, infectivity and species barriers of the
seed PrPRES (Bossers et al., 1997; Castilla et al., 2008, 2005; Kocisko
et al., 1995; Lucassen et al., 2003). We have demonstrated efﬁcient
ampliﬁcation of CWD PrPRES (PrPCWD) by serial protein misfolding
cyclic ampliﬁcation (sPMCA) using transgenic mice [Tg(CerPrP) mice]
over-expressing cervid PrPC as brain substrate (Green et al., 2008; Kurt
et al., 2007; Meyerett et al., 2008).
The plausibility of trans-species sPMCA is supported by cell-free
conversion studies which have shown that some conversion may
Fig. 1. NBH from deer, Tg(CerPrP)1536 mouse and ferret support ampliﬁcation of
PrPCWD. (A) Left panel: Ampliﬁcation of PrPCWD in white-tailed deer NBH initiated by
diluting CWD-positive brain deer brain 104 1:10 into the NBH. Serial PMCA was
performed with 1:2 dilutions into fresh NBH at each subsequent round for a total of 4
rounds. Two replicates each of PrPCWD-seeded (lanes 2–3) and unseeded (lanes 4–5)
samples are shown. Lane 1: A dilution (labeled −PMCA) frozen at −70 °C for the
duration of the experiment and equivalent to the ampliﬁed samples (labeled +PMCA)
after sPMCA. Lane 6: Deer NBH only, showing PrPC not digested with PK. (A) Right
panel: Ampliﬁcation in Tg1536 NBH was initiated by 1:2000–1:16,000 dilutions of
CWD-positive brain D10, followed by 1:2 dilutions into fresh NBH at each subsequent
round for a total of 4 rounds. Lane 1: Tg1536 NBH only, showing PrPC not digested with
PK. Lanes 2–3: Dilutions (labeled −PMCA) frozen at −70 °C for the duration of the
experiment and equivalent to the ampliﬁed samples (labeled+PMCA) after sPMCA. (B)
Ampliﬁcation in ferret NBHwas accomplished by 1:2000–1:16,000 dilutions of D10 and
4 rounds of sPMCA. Lane 1: Ferret NBH only, showing PrPC not digested with PK. Lanes
2–3: Dilutions (labeled −PMCA) frozen at −70 °C for the duration of the experiment
and equivalent to the ampliﬁed samples (labeled +PMCA) after sPMCA. “Seeded”:
samples seeded (+) or not seeded (−) with CWD-positive brain homogenate, “PK”:
samples digested (+) or not (−) with proteinase K, “PMCA”: samples subjected (+) or
not (−) to the sPMCA protocol described.
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et al., 1994; Piening et al., 2006; Priola et al., 2001; Raymond et al.,
2000). Here we apply sPMCA to demonstrate that brain homogenates
from species shown to be susceptible to CWD infection in vivo also
support ampliﬁcation of CWD prions in vitro (e.g. ferrets and
hamsters) whereas relatively resistant species [e.g. laboratory mice
(Mus spp.)] (Browning et al., 2004; Raymond et al., 2007; Sigurdson
et al., 2006; Williams and Young, 1980) do not. We extended this
approach to include species abundant in North America likely to be
exposed to CWD in the wild and that therefore have potential to serve
as reservoirs or laboratory models for CWD. Interestingly, we found
that all tested species that expressed asparagine at PrP position 170
supported trans-species ampliﬁcation of PrPCWD. All but one species
that expressed serine at PrP position 170 failed to support trans-
species ampliﬁcation of PrPCWD.
Results
Species susceptible to CWD infection in vivo
Deer, Tg(CerPrP) mouse, and ferret brain homogenates support
PrPCWD ampliﬁcation
To determine whether in vitro PrPCWD ampliﬁcation is demon-
strable in a susceptible species, we ﬁrst performed sPMCA using
normal-brain homogenates (NBH) fromwhite-tailed deer (Odocoileus
virginianus), a natural host for CWD. For these experiments, CWD-
positive deer brain 104 was diluted 1:10 into NBH from white-tailed
deer and subjected to sPMCAwith 1:2 dilutions into fresh NBH at each
successive round for a total of 4 rounds. We previously reported (Kurt
et al., 2007), and here conﬁrm, that deer brain homogenates support
∼5 fold increases in PrPRES in sPMCA (Fig. 1A, left panel), thus NBH
from the native CWD-susceptible species will support PrPC-to-PrPRES
conversion in vitro. We extended this work using NBH from Tg
(CerPrP)1536+/− mice, which express cervid PrPC at ∼4-fold the
concentration of that in deer brain. Using Tg(CerPrP)1536+/− NBH
and the CWD-positive deer brain D10, PrPRES ampliﬁcationwas at least
100 to 250-fold per round of PMCA (Kurt et al., 2007) and
ampliﬁcation was consistently achieved with starting dilutions up to
1:16,000, whereas the equivalent un-ampliﬁed dilutions (−PMCA
samples) were not detectable by Western blot (Fig. 1A, right panel).
To initiate trans-species sPMCA studies, we ﬁrst used NBH from
ferrets (Mustela putorius futo), a species that is susceptible to CWD
(Bartz et al., 1998; Sigurdson et al., 2008a), as a PrPC conversion
substrate. Ferret NBH supported ampliﬁcation at starting dilutions of
up to 1:16,000 of D10 (Fig. 1B).
In control experiments, D10 added to PrP-null mouse (PrP0/0)
brain homogenate did not amplify, indicating that the majority of PrPC
which is converted in sPMCA comes from the NBH vs. the PrPRES seed
material (not shown).
Species relatively less-susceptible to CWD infection in vivo
Hamster brain homogenates have varying ability to support
PrPCWD ampliﬁcation
Raymond et al. (2007) have demonstrated that Syrian golden
(Mesocricetus auratus), Chinese (Cricetulus griseus) and Armenian
(Cricetulus migratorius) hamsters are variably susceptible to intracer-
ebral inoculation of CWD. We have recently conﬁrmed the in vivo
susceptibility of Syrian golden hamsters to CWD (100% infected after
inoculation with D10, Hoover lab, unpublished). To investigate
differences in the ability of hamster species to support CWD
ampliﬁcation in vitro, we harvested NBH from Armenian, Chinese
and Syrian golden hamsters for sPMCA. We found that in three
experiments, Syrian golden hamster NBH supported ampliﬁcation of
1:8000–1:16,000 dilutions of PrPCWD (Fig. 2A). Chinese hamster NBH
consistently supported ampliﬁcation of up to 1:2000 dilutions of muledeer PrPCWD (Fig. 2B) and Armenian hamsters supported ampliﬁca-
tion of up to ∼1:1000 dilutions of D10 (Fig. 2C).
Mink brain homogenates did not support PrPCWD ampliﬁcation
American mink (Mustela vison) are closely related to ferrets and
differ from the latter by very few residues in PrP amino acid sequence
(Bartz et al., 1994), however, recent studies suggest that a relatively
strong species barrier exists restricting CWD transmission to mink by
even the intracranial route (Harrington et al., 2008). In our experiments
mink NBH did not support ampliﬁcation of PrPCWD even when a high
concentration (a 1:10 dilution) of D10 seedwas used in order to provide
asmuch seedmaterial as possible (Fig. 3). Higher concentrations of D10
were not feasible due to the difﬁculty in distinguishing potentially new
PrPRES from input seed. In these experiments Western blot PrPCWD
signals degraded with successive rounds of sPMCA (Fig. 3).
Species relatively resistant to CWD infection in vivo
BALB/c mouse brain failed to support PrPCWD ampliﬁcation
Common laboratory mouse (Mus) strains are considered to be
resistant to CWD (Browning et al., 2004; Raymond et al., 2007;
Sigurdson et al., 2006). Thereforewe evaluated NBH fromBALB/cmice
(selected as a common laboratory mouse strain expressing wild-type
Fig. 3. Mink NBH does not support ampliﬁcation of PrPCWD. For attempts to amplify
PrPCWD in mink, CWD-positive brain was diluted 1:10 (lanes 4–5) or 1:50 (lanes 6–7)
into the NBH and subjected to 3 rounds of sPMCA with 1:2 dilutions into fresh NBH at
each subsequent round (ﬁnal concentrations were 1:40 or 1:200, respectively). Lanes
2–3: Dilutions (labeled −PMCA) frozen at −70 °C for the duration of the experiment
and equivalent to the ampliﬁed samples after sPMCA. Lane 1: Mink NBH only, showing
PrPC not digested with PK.
Fig. 4. NBH from BALB/c, Tg(HuPrP-M129), and Tg(HuPrP-V129) mice do not support
ampliﬁcation of PrPCWD. (A) For attempts to amplify PrPCWD in BALB/c mice, CWD-
positive brainwas diluted 1:10 (4 replicates, lanes 3–6) into the NBH and subjected to 4
rounds of sPMCA. Lane 1: BALB/c mouse NBH only, showing PrPC not digested with PK.
Lane 2: A dilution (labeled −PMCA) frozen at −70 °C for the duration of the
experiment and equivalent to the ampliﬁed samples after sPMCA. (B) For ampliﬁcation
of PrPCWD in Tg mice expressing human PrP, CWD-positive brain was diluted 1:10 (2
replicates, lanes 4–5) or 1:50 (2 replicates, lanes 6–7) into each NBH and subjected to 3
rounds of sPMCA. Lanes 2–3: Dilutions (labeled −PMCA) frozen at −70 °C for the
duration of the experiment and equivalent to the ampliﬁed samples after sPMCA. Lane
1: Tg(HuPrP) mouse NBH only, showing PrPC not digested with PK.
Fig. 2. NBH from Syrian golden, Chinese and Armenian hamsters support ampliﬁcation
of PrPCWD. (A) Ampliﬁcation of PrPCWD in Syrian golden hamster NBH was initiated by
diluting CWD-positive brain D10 1:2000–1:16,000 into the NBH. Serial PMCA for all
hamsters was performedwith 1:2 dilutions into fresh NBH at each subsequent round for
a total of 4 rounds. Lanes 2–5: Dilutions (labeled −PMCA) frozen at −70 °C for the
duration of the experiment and equivalent to the ampliﬁed samples after sPMCA. (B)
Ampliﬁcation of PrPCWD in Chinese hamster NBH was initiated by diluting CWD-
positive brain D10 1:500–1:2000 into the NBH. Lanes 2–4: Dilutions (labeled−PMCA)
frozen at −70 °C for the duration of the experiment and equivalent to the ampliﬁed
samples after sPMCA. (C) Ampliﬁcation of PrPCWD in Armenian hamster NBH was
initiated by diluting CWD-positive brain D10 1:500–1:1000 into the NBH. Lanes 2–4:
Dilutions (labeled −PMCA) frozen at −70 °C for the duration of the experiment and
equivalent to the ampliﬁed samples after sPMCA. A, B and C, Lane 1: Hamster NBH only,
showing PrPC not digested with PK. “Seeded”: samples seeded (+) or not seeded (−)
with CWD-positive brain homogenate, “PK”: samples digested (+) or not (−) with
proteinase K, “PMCA”: samples subjected (+) or not (−) to the sPMCA protocol
described.
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BALB/cNBHdid not support ampliﬁcation of PrPCWD, evenwhen a 1:10
starting dilution of D10 seedwas used (Fig. 4A). Aswith otherNBH that
did not support ampliﬁcation, Western blot PrPCWD signals degraded
with each successive round.
Human PrP transgenic mouse brain failed to support PrPCWD
ampliﬁcation in vitro
We attempted to amplify PrPCWD using NBH from two strains of
transgenic mice hemizygous for transgenes expressing human PrP.We
generated Tg mice expressing human PrP encoding either M or V at
codon 129 by microinjection of fertilized embryos from FVB/Prnp0/0
mice. The resulting founders were mated to FVB/Prnp0/0 mice toproduce lines that were hemizygous for the transgene array.
Expression of HuPrPC in the CNS of mice was examined by Western
blotting with mAb 6H4. Mice from the Tg(HuPrP-M129)6816+/− and
Tg(HuPrP-V129)7823+/− lines expressed HuPrP in the CNS at
approximately 16- and 5-fold the level of PrP in the brains of wild-
type mice. Neither strain NBH supported ampliﬁcation of 1:10 or 1:50
starting dilutions of D10 (Fig. 4B).
Species for which CWD susceptibility is unknown
Prairie dog brain homogenates failed to support PrPCWD ampliﬁcation
Prairie dogs (Cynomys ludovicianus) are ground-dwelling rodents
prevalent in the Western United States, including within CWD-
Fig. 5. Prairie dog, domestic cat, wild coyote and macaque monkey NBH do not support
ampliﬁcation of PrPCWD (A) For attempts to amplify PrPCWD in prairie dogs, CWD-
positive brain was diluted 1:10 (2 replicates, lanes 4–5) or 1:50 (2 replicates, lanes 6–
7) into the NBH and subjected to 4 rounds of sPMCA. Lanes 2–3: Dilutions (labeled
−PMCA) frozen at −70 °C for the duration of the experiment and equivalent to the
ampliﬁed samples after sPMCA. Lane 1: Prairie dog NBH only, showing PrPC not
digested with PK. (B) For the cat experiment shown (representative of 3 cats), CWD-
positive brain was diluted 1:50 into the NBH and subjected to 8 rounds of sPMCA (4
replicates, lanes 4–7). Lane 2: A dilution (labeled −PMCA) frozen at −70 °C for the
duration of the experiment and equivalent to the ampliﬁed samples after sPMCA. Lane
1: Cat NBH only, showing PrPC not digested with PK. (C) For attempts to amplify
PrPCWD in coyote, CWD-positive brain was diluted 1:10 (2 replicates, lanes 4–5) and
1:50 (2 replicates, lanes 6–7) and subjected to 4 rounds of sPMCA. Lanes 2–3: Dilutions
(labeled −PMCA) frozen at −70 °C for the duration of the experiment and equivalent
to the ampliﬁed samples after sPMCA. Lane 1: Coyote NBH only, showing PrPC not
digested with PK. (D) For attempts to amplify PrPCWD in macaque NBH, CWD-positive
brain was diluted 1:50 and subjected to 4 rounds of sPMCA (2 replicates, lanes 3–4).
Lane 2: A dilution (labeled −PMCA) frozen at −70 °C for the duration of the
experiment and equivalent to the ampliﬁed samples after sPMCA. Lane 1: Macaque
NBH only, showing PrPC not digested with PK.
Fig. 6. NBH from prairie vole and Peromyscusmice support ampliﬁcation of PrPCWD. (A)
For ampliﬁcation of PrPCWD in prairie voles, CWD-positive brain was diluted 1:50 (2
replicates, lanes 4–5) or 1:100 (2 replicates, lanes 6–7) into the NBH and subjected to 3
rounds of sPMCA. Lanes 2–3: Dilutions (labeled −PMCA) frozen at −70 °C for the
duration of the experiment and equivalent to the ampliﬁed samples after sPMCA. Lane
1: PrPC not digested with PK. (B) For ampliﬁcation of PrPCWD in Peromyscusmice, CWD-
positive brainwas diluted 1:50 (4 replicates, lanes 4–7) into the NBH and subjected to 3
rounds of sPMCA. Lanes 2–3: Dilutions (labeled −PMCA) frozen at −70 °C for the
duration of the experiment and equivalent to the ampliﬁed samples after sPMCA. Lane
1: PrPC not digested with PK.
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dog brain did not support PrPC-to-PrPRES conversion when seeded
with 1:10 or 1:50 dilutions CWD-positive brain (Fig. 5A).
Domestic cat and coyote brain homogenates did not support
PrPCWD ampliﬁcation
Canid and felid carnivore species may be directly exposed to
CWD by predation and scavenging. Domestic cats (Felis catus), in
addition to exotic felids, are susceptible to BSE, leading to cases of
feline spongiform encephalopathy in several European countries
(Pearson et al., 1992; Sigurdson and Miller, 2003; Wells and McGill,
1992). However, their susceptibility to CWD has not been deter-
mined. Interestingly, cat NBH did not support PrPCWD ampliﬁcation
(Fig. 5B).
We harvested NBH from one coyote (Canis latrans) and performed
trans-species sPMCA. Coyote NBH also did not support ampliﬁcation
of PrPCWD (Fig. 5C). We subjected NBH that did not support sPMCA,
such as from cat and coyote, to up to 8 rounds of PMCA and no change
in results was produced (see cat, Fig. 5B).
Macaque brain homogenates did not support PrPCWD ampliﬁcation
At least one species of non-human primate is susceptible to CWD
(Marsh et al., 2005). We obtained NBH from three rhesus macaques
(Macaca mulatta) for trans-species sPMCA. Macaque NBH did not
support ampliﬁcation of PrPCWD (Fig. 5D).Prairie vole and ﬁeld mouse brain homogenates support
PrPCWD ampliﬁcation
In our search for non-cervid species susceptible to CWD we
examined PrPC-to-PrPRES conversion using NBH from several North
American rodents. These studies were prompted in part by thework of
Chandler (1971), Chandler and Turfrey, (1972) andNonno et al. (2006)
demonstrating that ﬁeld voles (Microtus agrestis) and bank voles
(Myodes glareolus) are susceptible to scrapie. We therefore assessed
the prairie vole (Microtus ochrogaster), a common North American
species, for its capacity to amplify PrPCWD in trans-species sPMCA. In
three experiments, we found that prairie vole NBH consistently
supported ampliﬁcation of PrPCWD at starting dilutions of up to 1:50
to 1:100D10 brainwithin four rounds of sPMCA (Fig. 6A). These results
were similar to those obtained using ferret, Chinese hamster and
Tg1536 mouse NBH, and suggested to us that prairie voles may be
susceptible to CWD, a hypothesis we are currently testing in ongoing
infectivity studies. Concurrently, we became aware of the work of
Johnson, Heisey and colleagues who have reported ongoing in vivo
studies indicating that other North American vole species are
susceptible to CWD (C. Johnson, D. Heisey and colleagues, personal
communication).
We next examined two species of common North American ﬁeld
mice, Peromyscus leucopus and Peromyscus maniculatus bairdii, by
trans-species sPMCA. P.m. bairdii in particular has a geographic range
that overlaps that of CWD-positive cervids (Baker, 1983). Both species
of Peromyscus mice consistently supported ampliﬁcation of dilutions
of D10 up to 1:100 (Fig. 6B). Studies examining the in vivo
susceptibility of Peromyscus mice to CWD are also in progress. Again
separately, Heisey, Johnson and colleagues. have gathered data that
suggest both of these Peromyscus species are susceptible to CWD (C.
Johnson, D. Heisey and colleagues, personal communication).
Cyclic ampliﬁcation of PrPCWD correlated with position 170 of the
substrate species PrP
Host PrP primary structure is associated with susceptibility to
particular TSEs (Jewell et al., 2005; Laplanche et al., 1993; O'Rourke
Fig. 7. Trans-species ampliﬁcation of PrPCWD correlated with position 170 of the
substrate species PrP. PrP sequence 170–175 (part of the β2–α2 loop) of the species
used for NBH in trans-species sPMCA. All the species tested expressed asparagine (N) or
serine (S) at position 170. The ferret sequence encodes leucine (L) at position 175.
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structures of the animals we used for sPMCA (sequencing of prairie
dog Prnp has not been successful) in an effort to ﬁnd amino acids that
might help explain why NBH from certain species support sPMCA
while others do not. Of particular interest was the loop between the
β2 strand and α2 helix (PrP residues 166–175), which is more stable
in elk than mice (Gorfe and Caﬂisch, 2007; Gossert et al., 2005) and
may contribute to the transmission barrier between these species
(Sigurdson et al., 2008b). Of the species we studied, all of those that
express asparagine at PrP position 170 (i.e. Tg(CerPrP)1536 mouse,
Peromyscus mouse, prairie vole, Syrian, Chinese and Armenian
hamster) supported ampliﬁcation of PrPCWD by sPMCA (Fig. 7). In
contrast, only one (ferret) of the eight species (ferret,Musmouse, two
strains of Tg(HuPrP) mouse, cat, coyote, mink, macaque) that express
serine at position 170 supported ampliﬁcation of PrPCWD (Fig. 7),
indicating that 170N facilitates PrPCWD ampliﬁcation. We did not ﬁnd
correlations at any other PrP amino acid positions.
Discussion
Herewe demonstrate that CWDprions can be ampliﬁed in normal-
brain homogenates (NBH) from several outbred species whose habitat
overlaps with that of free-ranging cervids. Our ﬁndings complement
and extend recent studies that suggest sPMCA results may correlate
with susceptibility to prion diseases (Castilla et al., 2008; Green et al.,
2008). We have begun in vivo analyses to assess whether prairie voles
(Microtus spp.) or ﬁeld mice (Peromyscus spp.) are susceptible to CWD
infection and whether species adaptation occurs via trans-species
sPMCA. The recent ﬁndings of Castilla et al. (2008) and Green et al.
(2008) provide support for the plausibility of the latter. Moreover,
reports from several investigators provide evidence that PrPRES
generated by sPMCA is infectious (Castilla et al., 2008, 2005; Deleault
et al., 2007; Green et al., 2008).
In the present study, sPMCA experiments were considered positive
if they resulted in the generation of new protease-resistant material in
PrPCWD-seeded (+PMCA) samples but not in non-PrPCWD-seeded
(−PMCA) samples. Accurate calculation of comparative ampliﬁcation
efﬁciency using non-cervid NBH can be complicated by differences in
the antibody afﬁnity and PK sensitivity of cervid (our PrPCWD source)
vs. non-cervid prion proteins. To avoid this potential pitfall we
attempted to estimate relative ampliﬁcation efﬁciency by ﬁnding the
dilutions of input PrPCWD which could consistently be ampliﬁed
within 3–4 rounds of sPMCA. We performed up to eight rounds of
sPMCA, used different CWD-positive seed sources (D10 and 104), andused several detection antibodies in attempts to obtain conversion in
species that did not support PrPCWD ampliﬁcation, but this did not
result in PrPC conversion in those species. We performed conﬁrmatory
Western blots to ensure that our ﬁndings could be replicated and
interpreted consistently. These assays increased our conﬁdence that
all PrPRES generated in our experiments was protease-resistant and
that all NBH PrPC was digested and did not contribute to signal as
background.
The detectable signal of input PrPCWD (−PMCA) samples in
species that did not support sPMCA is due to the high concentration of
starting material used in attempt to initiate sPMCA in these species.
For example, we used a 1:10 input dilution of PrPCWD in attempts to
obtain conversion in BALB/c mice and HuPrP mice (Fig. 4). The ﬁnal
dilution of this sample after 4 rounds of PMCA was 1:80 (Round
1=1:10, Round 2=1:20, Round 3=1:40, Round 4=1:80), which is
detectable byWestern blot without PMCA (see−PMCA samples). The
samples subjected to PMCA (+PMCA) sometimes exhibit a weaker
Western blot signal than predicted based on the −PMCA samples,
which is indicative of a failure to support ampliﬁcation. The
deterioration of the signal is most likely caused by the increased
exposure of PrPCWD to proteinase K (PK) following physical separation
of PrPCWD aggregates (Piening et al., 2005). Proteolysis during PMCA
is unlikely given that protease inhibitors were added to all homo-
genates. We have observed deterioration of PrPRES signals when using
NBH from species known to be TSE-resistant, such as transgenic
Prnp0/0 mice (not shown). The variability in input PrPCWD signals
between blots is explained by the different concentrations of PK used
for each species (due to innate differences in PrPC sensitivity and the
need to completely digest NBH PrPC) and the different antibodies
used for Western blotting (e.g. deer and BALB/c mouse samples were
both digested with 100 μg/ml PK, but different antibodies were used
for detection).
Our ongoing in vivo studies should yield data to aid in correlating
ampliﬁcation efﬁciency in vitro with susceptibility in vivo, an
obviously critical issue. Thus far we have several non-cervid species
(transgenic CerPrP mice, ferrets, hamsters, wild-type Mus mice,
transgenic HuPrP mice, Peromyscus mice) in which the in vivo and in
vitro results have generally correlated. However, in vivo and in vitro
species barriers to conversion may be affected by prion strain,
infectious titer of the inoculum, the genetic background of the
recipient species, and PrPC expression levels. One of our PrPCWD
sources (D10) ampliﬁed in NBH from several hamster species, which
is consistent with the higher attack rates of this inoculum in Syrian
golden hamsters (100%, Hoover lab, unpublished) than reported with
other CWD inocula (Raymond et al., 2007). Corresponding in vivo
studies in many non-cervid species (e.g. felids, canids) would require
lengthy observation periods before deﬁnitive conclusions regarding
susceptibility could made.
PrPC concentration has also been shown to play a role in
determining the ability to support ampliﬁcation of PrPCWD (Kurt et
al., 2007). We estimated the PrPC concentration of brain homogenates
from several species by Western blot and did not ﬁnd differences that
could explain our results (data not shown). Some of the species we
used, e.g. the transgenic HuPrP mice, express high levels of PrPC and
still did not support ampliﬁcation.
PrP sequence also inﬂuences the efﬁciency of in vitro prion
conversion and species barriers to disease transmission (Bossers
et al., 1997; Nonno et al., 2006; Piening et al., 2006; Priola et al., 2001).
We sequenced the PrP gene from each of the species examined
(sequencing of prairie dog Prnp has not yet been successful) for which
published data were not available, deduced the primary structures,
and compared these with published sequences for the other species.
The amino acids present at position 222 (225 in deer) and 92 (96 in
deer), both of which are associated with susceptibility to CWD in
cervids (Jewell et al., 2005; O'Rourke et al., 1999, 2004), did not
correlate with ability or inability to support ampliﬁcation.
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stable in elk than mice primarily due to the presence of asparagine
rather than serine at position 170 (Gorfe and Caﬂisch, 2007; Gossert
et al., 2005). Of the animals we used, all of those that express
asparagine at PrP position 170 (i.e. Tg(CerPrP)1536 mouse, Peromys-
cus mouse, prairie vole, Syrian, Chinese and Armenian hamsters)
supported ampliﬁcation of PrPCWD by sPMCA. In contrast, only one
(ferret) of the eight animals (laboratory mouse, both Tg(HuPrP) mice,
cat, coyote, ferret, mink, macaque) that express serine at position 170
supported ampliﬁcation of PrPCWD. The mobility of the loop is
inﬂuenced by other residues such as Phe175 (Gorfe and Caﬂisch,
2007), and the unique presence of leucine, rather than phenylalanine
(and the corresponding phenyl ring), at position 175 of ferret PrP may
induce greater stability via side chain hydrogen bonding. This might
explain the greater PrPC-to-PrPCWD conversion observed when we
used ferret NBH, despite the presence of Ser170. The loop region,
including residues 170 and sheep polymorphism 171, is thought play a
role in determining PrP conversion/susceptibility in several species
(Bossers et al., 1997; Christen et al., 2008; Gorfe and Caﬂisch, 2007;
Piening et al., 2006; Sigurdson et al., 2008b; Westaway et al., 1994).
We did not ﬁnd correlations with any other PrP amino acid positions,
including 155 (Piening et al., 2006; Priola et al., 2001).
In our experiments, mink brain homogenates did not support
sPMCA even though this species exhibits some susceptibility to CWD
in vivo (Harrington et al., 2008). This clearly supports the premise that
other factors in the brain and periphery besides PrP sequence
(Deleault et al., 2005, 2003; Sigurdson et al., 2002, 1999) affect
susceptibility in vivo. This premise is supported by studies that show
host genetic background affects TSE susceptibility (Lloyd et al., 2001)
and demonstrates that extrapolations from negative in vitro conver-
sion results should be made with caution.
This study demonstrates successful trans-species sPMCA using a
diverse range of animal species. Many of these ﬁndings corroborate
data from other studies. For instance, Bartz et al. (1998) and Sigurdson
et al. (2008a) demonstrated that ferrets are susceptible to CWD in
vivo. We found that ferret NBH supported ampliﬁcation of high
dilutions of input PrPCWD. Raymond et al. (2007)) demonstrated that
hamsters are variably susceptible to CWD in vivo. We found that the
capacity of hamster NBH to amplify PrPCWD depended on the species:
Syrian golden and Chinese hamster NBH supported robust ampliﬁca-
tion of PrPCWD, and Armenian hamster NBH supported minimal
ampliﬁcation. As might have been anticipated, wild-type laboratory
mouse (Mus) NBH did not support sPMCA, just as these animals fail to
support CWD ampliﬁcation in vivo (Browning et al., 2004; Raymond
et al., 2007; Sigurdson et al., 2006;Williams and Young, 1980). Finally,
we were not able to amplify PrPCWD using NBH from HuPrP transgenic
mice, a result which is consistent with ﬁndings from the in vivo
studies of Kong et al. (2005) and Tamguney et al. (2006) using
transgenic mice expressing human PrPC.
We are mindful that susceptibility to prion disease is affected by
dose, route of inoculation, host lifespan and other factors, and
therefore is difﬁcult to quantify. Although our sPMCA results (with
the exception of mink) were consistent with in vivo studies
demonstrating susceptibility or resistance to CWD in the same
species, in vivo studies are still the gold standard for determining
TSE susceptibility. Thus we have initiated in vivo studies in a subset of
species that support sPMCA as described here, in an effort to explore
whether sPMCA can actually be used to predict in vivo susceptibility.
Materials and methods
Transgenic mice encoding cervid PrP
Transgenic mice expressing cervid PrP were generated in the
Telling lab (Browning et al., 2004) and have been used previously in
sPMCA (Green et al., 2008; Kurt et al., 2007; Meyerett et al., 2008).Production of transgenic mice encoding human PrP
To generate transgenic (Tg) mice expressing human PrP encoding
eithermethionine (M) or valine (V) at codon 129, referred to asHuPrP-
M129 and HuPrP-V129 respectively, coding sequences were excised
from the cloning vector pSP72 using SalI andXhoI and inserted into the
XhoI restriction site inMoPrP.Xho (Borchelt et al.,1996), a derivative of
the ‘half genomic’ Prnp expression vector (Fischer et al.,1996). TheNotI
fragments encompassing theHuPrP expression cassetteswere puriﬁed
by electrophoresis in low melting temperature agarose in the absence
of ethidium bromide. DNA was recovered by phenol and chloroform
extraction followed by dialysis against microinjection buffer (Tris–Cl
10 mM, pH 7.5/EDTA 0.1 mM). After estimation of the DNA
concentration by quantitative gel electrophoresis, the DNAwas diluted
to a ﬁnal concentration of 2 ng/μl for pronuclear microinjection of
fertilized FVB/Prnp0/0 oocytes. Founder mice were identiﬁed by tail
biopsy and extraction of genomic DNA using a Beckman Biomek FX
robotics station followed by PCR screening for the presence of the
transgene. Approximately 1 cm of tail tissue was digested overnight at
55 °C with proteinase K (0.5 mg/ml ﬁnal concentration) in 50mMTris
pH8.0, 100 mM EDTA, 0.5% SDS, the DNA extracted with phenol and
chloroformand concentrated byethanol precipitation. Estimates of the
levels of PrP expression in the CNS of F1 offspring were determined by
semi-quantitative immuno dot blotting. Aliquots of Tg brain homo-
genates containing equal amounts of total protein, determined by
bicinchoninic acid assay (BCA) (Pierce, Rockford, IL), were subjected to
two-fold serial dilutions and bound toWhatmanProtran nitrocellulose
0.45 μM membrane ﬁlters. Blots were probed with anti-PrP mono-
clonal antibody (mAb) 6H4 (Prionics), developed using enhanced
chemiluminescence (ECL-Plus) and exposed to X-ray ﬁlm. Levels of
transgene expression were estimated by comparison to PrP levels in
brain extracts of wild-type mice. Transgenic F1 offspring were mated
with FVB/Prnp0/0 to establish individual Tg lines. In all cases, Tg mice
weremaintained on a FVB/Prnp0/0 background. Tg(HuPrP-M129)6816
+/− mice and Tg(HuPrP-V129)7823+/− mice were used in these
studies.
Sources and preparation of brain homogenates
Donor animals were euthanized according to ACUC approved
protocols and immediately perfused (except prairie dogs), to remove
as much blood as possible, with phosphate buffered saline (PBS) plus
5 mM EDTA. At least two individuals (in most cases three) of each
species, and one coyote, were used. Deer brain was provided by David
Osborn (Warnell School of Forestry, University of Georgia). Tg(CerPrP)
1536+/− mice (Browning et al., 2004) were housed at CSU. Ferrets
were obtained from Marshall Farms Inc. BALB/c mice were provided
by James Perry and Anne Avery at CSU. Prairie deer mice and white-
footed mice (Peromyscus maniculatus bairdii and P. leucopus, respec-
tively) were obtained from the University of South Carolina Genetic
Stock Center and were housed at CSU. Prairie voles (Microtus
ochrogaster) were obtained from Thomas Curtis (University of
Oklahoma) and were housed at CSU. Coyote brain (Canis latrans)
was obtained from the National Wildlife Research Center Utah Field
Station with the help of John Shivik and Stacey Brummer. Mink brain
was a gift from Jason Bartz (Creighton University). Syrian Golden
hamsters were obtained from Harlan Labs. Armenian and Chinese
hamsters were a gift from Greg Raymond, Richard Race, Brent Race
and Byron Caughey at the Laboratory of Persistent Viral Diseases,
Rocky Mountain Veterinary Branch, NIAID, NIH. Cat brain was
harvested from animals that were involved in other studies being
conducted in the CSU pathogen-free facility and were made available
by Sue VandeWoude. Prairie dogs were obtained from the Black-
Footed Ferret Conservation Center, US Fish and Wildlife Service,
thanks to Paul Marinari. Macaque monkey brain was obtained from
Tulane Primate Research Center. Transgenic mice expressing human
Table 1
Antibodies used for the detection of PrP
Species Antibodies that detect PrP
Deer and Tg(CerPrP)1536 mice Bar224, 12F10, L42, SAF53, SAF54,
SAF70, SAF83, SAF84, 8G8, 12B2, R30, R505
Ferret, mink Bar224, 12F10, L42
Hamster Bar224, SAF83, 3F4, 3O8
Prairie vole Bar224, SAF83, SAF84
Peromyscus mice SAF83
Mus mice SAF83, 6H4
Tg(HuPrP) mice 12F10, L42, 6H4
Cat Bar224, L42, 3F4, 3O8, 7D9
Coyote Bar224, 12F10, L42, SAF84, 7D9
Praire dog Bar224
Macaque Bar224, 12F10, L42, 3F4, 3O8, 7D9
Each species was screened to ﬁnd antibodies for Western blot detection of PrP. These
antibodies were used in an attempt to detect newly formed PrPRES in trans-species
sPMCA experiments.
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were housed at the University of Kentucky/Telling lab.
Preparation of brain homogenates
Normal-brain homogenates (NBH) were prepared as previously
described (Kurt et al. 2007).
CWD-positive brain homogenates were prepared as follows: (1)
D10 was prepared from a CWD-infected mule deer (generously
provided byMichaelMiller, Colorado Division ofWildlife), and (2) 104
was prepared from a white-tailed deer experimentally infected with
CWD source LAO1 (Colorado Division of Wildlife) and housed at CSU
(Mathiason et al., 2006). The CWD-positive brain homogenates were
prepared at a ﬁnal concentration of 20% (w/v) andwere not subjected
to centrifugation.
Serial PMCA procedure
To eliminate possible contamination, NBH was thawed on ice and
loaded into 96well plates (TempPlate III, USAScientiﬁc) in a laboratory
that was never used for prion research. The plate was then transported
to the prion research laboratory where CWD-positive brain homo-
genate was diluted into the NBH to comprise a total volume of 50 μl
(unseeded, NBH-only controls also comprised 50 μl). Non-ampliﬁed
dilutions (−PMCA inﬁgures)were frozen at−70 °C for the duration of
the experiment for comparisonwith ampliﬁed (+PMCA) samples. The
PrPCWD concentrations of −PMCA samples were equivalent to
corresponding +PMCA samples after sPMCA. The plate was placed
in a Misonix 3000 sonicator containing 200 ml distilled water, leaving
2–3 mm between the horn and the plate bottom. The plate was
subjected to 40 s bursts at power level 7 followed by 30 min
incubations at 37 °C for 48 h (this comprising 1 round of PMCA), and
the samples were diluted 1:2 into fresh NBH for each new round
(control dilutions were diluted identically at the start of the
experiment and were then frozen, not ampliﬁed). These settings
yielded the most efﬁcient ampliﬁcation of PrPCWD in our experiments.
Electrophoresis and Western blotting
After sPMCA, samples were digested with proteinase K (PK)
(Invitrogen) before transfer and blotting. Due to innate differences in
protease sensitivity of PrPC between each substrate species, equivalent
amounts of parallel non-seeded samples were used as a guide to
assure complete PrPC digestion. Samples using Tg(CerPrP)1536+/−
mouse, prairie dog, mink, coyote and cat NBH as substrate were
brought to a ﬁnal SDS concentration of 0.25% prior to digestion with
100 μg/ml PK for 30min at 37 °C followed by 10min at 45 °C. Ferret, Tg
(HuPrP)6816+/− and Tg(HuPrP)7823+/− substrates were digested
similarly but without incubation at 45 °C. Deer, hamster, vole, Pero-
myscus and BALB/c mouse substrate samples were digested with
100 μg/ml PK, and macaque with 50 μg/ml PK, for 30 min at 37 °C. All
samples (including unseeded, NBH-only controls) had a ﬁnal volume
of 10 μl after addition of PK.
Electrophoresis and transfer to PVDF membranes were performed
as previously described (Kurt et al., 2007). We screened each species
to ﬁnd optimal antibodies based on PrPC detection (Table 1).
Antibodies used for manuscript ﬁgures are as follows: for detection
of PrP in Tg(CerPrP)1536+/−, cat, coyote, ferret, prairie dog, mink, vole
and deer samples, membranes were incubated in Bar224 mAb (a gift
from Jacques Grassi, CEA, Saclay, France) conjugated directly to horse
radish peroxidase (HRP) for at least 1 h. For detection of hamster,
Peromyscus and BALB/c Mus samples, membranes were incubated in
mAb SAF83 (Cayman Chemical) for at least 1 h, washed several times,
then incubated in HRP-labeled goat anti-mouse IgG secondary Ab
(Jackson Labs) diluted 1:20,000. For detection of PrP in Tg(HuPrP)
6816+/− and Tg(HuPrP)7823+/− mouse samples, membranes wereincubated in mAb 12F10 (Cayman Chemical) for at least 1 h, washed
several times, then incubated in HRP-labeled goat anti-mouse IgG
secondary Ab diluted 1:20,000. Macaque samples were incubated in
mAb 7D9 (Abcam) for at least 1 h, washed several times, then
incubated in HRP-labeled goat anti-mouse IgG secondary Ab diluted
1:20,000. All membranes were washed several times in dH20
containing 0.2% Tween-20 before application of ECL-plus™ chemilu-
minescent reagents (Amersham). Data were generated using a digital
Fuji-Doc™ gel documentation system (Fuji) with automated detection
of saturation limits, and densitometric analyses were performed with
ImageGauge™ quantiﬁcation software. Successful ampliﬁcation was
indicated by increases in PrPCWD relative to−PMCA samples or by the
presence, after sPMCA, of protease-resistant bands in samples
containing otherwise undetectable concentrations of PrPCWD, con-
current with the absence of PrPCWD in non-seeded, NBH-only control
samples. We analyzed samples after 3 or 4 rounds of sPMCA and
performed up to eight rounds of sPMCA in attempts to obtain
conversion in those species that did not support PrPCWD ampliﬁcation.
Data shown are representative of multiple experiments using 2–3
individuals of each species and one coyote.
PCR and PRNP sequencing
DNA was extracted from NBH of coyote, Peromyscus mice and
prairie voles by addition of 500 μl chloroform-phenol isoamyl-alcohol
(IAA) to 1 ml NBH. The samples were then inverted 10 times and
centrifuged at 12,000 ×g for 5 min at room temperature before the
aqueous layer was removed and combined with IAA and these steps
repeated as described. The aqueous layer was then removed and
mixed with 0.1 volumes of 3M sodium acetate, followed by 2.5
volumes of 100% ethanol. Samples were stored at −20 °C for 48 h
before centrifugation at 14,000 ×g for 30 min at 4 °C, at which time
the ﬂuid was decanted and the pellet allowed to dry. The DNAwas re-
suspended in 50 μl of 1× TE buffer. For Polymerase Chain Reaction
(PCR), the following forward and reverse primers were used for each
species: (1)Microtus ochrogaster: GTGGAACAAGCCCAGTAAGCCAAA and
ATGGTGATGTTGACGCAATCGTGC, ATGGACTGATGTGGGTCTCTGCAA and
CGTGCACGAAGTTGTTCTGGTTGT, (2) Peromyscus bairdi i:
ACTCTTTGTGGCTACGTGGACTGA and ACGGGCCGATAGTACACTTGGTTA,
(3) P. leucopus: ACTCTTTGTGGCTACGTGGACTGA and TGACTGTGTGCT-
GCTTGATGGTGA, and (4) Canis latrans: GGTGAAAAGCCACATAGGCGGC
and CAGCGAGATGAGGAGGATCACGG. PCR products were excised from
the gel using Invitrogen PureLink Quick Gel Extraction Kit and were
cloned using the TOPO TA Cloning Kit (K4500-01, Invitrogen). At least
two clones of from each species were sequenced (Macromolecular
Resources, Colorado State University) (GenBank accession nos.
FJ232956, FJ232957, FJ232958 and FJ232959) and then used to deduce
amino acid sequence.
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